Although the multi-target and MET inhibitor cabozantinib showed only a modest effect on GBM [31] (weighted by a high adverse events rate), the oral MET inhibitor capmatinib is under investigation for patients with GBM, in combination with bevacizumab (NCT02386826). The gene discussed is MET; the disease is glioblastoma.